UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): March 12, 2009
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
001-15281
(Commission File Number)
|
|
76-0233274
(I.R.S. Employer Identification No.) |
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2 below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
| Item 7.01 |
|
Regulation FD Disclosure. |
The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K
and, according to general instruction B.2. thereunder, the information in this Current Report shall
not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that Section. The information in this Current Report shall
not be incorporated by reference into any registration statement pursuant to the Securities Act of
1933.
Repros Therapeutics Inc. (the “Company”) today announced that it will report financial results
for the quarter and year ended December 31, 2008, before the market opens on March 16, 2009. The
Company’s management will hold a conference call to provide an update on the Company’s progress and
to answer investor questions at 12:00 noon CT on the same day.
Conference Call Information
Domestic callers: 866-282-4865
International callers: 702-495-1343
Passcode: 90105059
Approximately two hours after the conclusion of the conference call, a replay will be
available for 48 hours. To access the replay, dial 800-642-1687 (Domestic) and 706-645-9291
(International) and enter the passcode #90105059. The replay will also be available on the the
Company’s website, www.reprosrx.com approximately 24 hours after the call ends.
A copy of the Company’s press release is attached hereto as Exhibit 99.1. The foregoing
description of the press release is qualified in its entirety by reference to the attached exhibit.
|
|
|
| Item 9.01 |
|
Financial Statements and Exhibits. |
(d) Exhibits.
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Description |
| |
|
|
|
|
| |
99.1 |
|
|
Press Release dated March 12, 2009. |